SwePub
Sök i LIBRIS databas

  Extended search

onr:"swepub:oai:DiVA.org:uu-311601"
 

Search: onr:"swepub:oai:DiVA.org:uu-311601" > Design and Rational...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist
  • Cannon, Christopher P.Harvard Clin Res Inst, 930 Commonwealth Ave, Boston, MA 02215 USA.;Brigham & Womens Hosp, Div Cardiovasc, 75 Francis St, Boston, MA 02115 USA.;Harvard Med Sch, Boston, MA USA. (author)

Design and Rationale of the RE-DUAL PCI Trial : A Prospective, Randomized, Phase 3b Study Comparing the Safety and Efficacy of Dual Antithrombotic Therapy With Dabigatran Etexilate Versus Warfarin Triple Therapy in Patients With Nonvalvular Atrial Fibrillation Who Have Undergone Percutaneous Coronary Intervention With Stenting

  • Article/chapterEnglish2016

Publisher, publication year, extent ...

  • 2016-08-26
  • Wiley,2016
  • electronicrdacarrier

Numbers

  • LIBRIS-ID:oai:DiVA.org:uu-311601
  • https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-311601URI
  • https://doi.org/10.1002/clc.22572DOI

Supplementary language notes

  • Language:English
  • Summary in:English

Part of subdatabase

Classification

  • Subject category:ref swepub-contenttype
  • Subject category:art swepub-publicationtype

Notes

  • Antithrombotic management of patients with atrial fibrillation (AF) undergoing coronary stenting is complicated by the need for anticoagulant therapy for stroke prevention and dual antiplatelet therapy for prevention of stent thrombosis and coronary events. Triple antithrombotic therapy, typically comprising warfarin, aspirin, and clopidogrel, is associated with a high risk of bleeding. A modest-sized trial of oral anticoagulation with warfarin and clopidogrel without aspirin showed improvements in both bleeding and thrombotic events compared with triple therapy, but large trials are lacking. The RE-DUAL PCI trial (NCT 02164864) is a phase 3b, a strategy of prospective, randomized, open-label, blinded-endpoint trial. The main objective is to evaluate dual antithrombotic therapy with dabigatran etexilate (110 or 150 mg twice daily) and a P2Y12 inhibtor (either clopidogrel or ticagrelor) compared with triple antithrombotic therapy with warfarin, a P2Y12 inhibtor (either clopidogrel or ticagrelor, and low-dose aspirin (for 1 or 3 months, depending on stent type) in nonvalvular AF patients who have undergone percutaneous coronary intervention with stenting. The primary endpoint is time to first International Society of Thrombosis and Hemostasis major bleeding event or clinically relevant nonmajor bleeding event. Secondary endpoints are the composite of all cause death or thrombotic events (myocardial infarction, or stroke/systemic embolism) and unplanned revascularization; death or thrombotic events; individual outcome events; death, myocardial infarction, or stroke; and unplanned revascularization. A hierarchical procedure for multiple testing will be used. The plan is to randomize similar to 2500 patients at approximately 550 centers worldwide to try to identify new treatment strategies for this patient population.

Subject headings and genre

Added entries (persons, corporate bodies, meetings, titles ...)

  • Gropper, SavionBoehringer Ingelheim Pharma GmbH & Co KG, Ingelheim, Germany. (author)
  • Bhatt, Deepak L.Brigham & Womens Hosp, Div Cardiovasc, 75 Francis St, Boston, MA 02115 USA.;Harvard Med Sch, Boston, MA USA. (author)
  • Ellis, Stephen G.Cleveland Clin, Cleveland, OH 44106 USA. (author)
  • Kimura, TakeshiKyoto Univ, Grad Sch Med, Dept Cardiovasc Med, Kyoto, Japan. (author)
  • Lip, Gregory Y. H.Univ Birmingham, City Hosp, Inst Cardiovasc Sci, Birmingham, W Midlands, England. (author)
  • Steg, Ph. GabrielUniv Paris Diderot, Sorbonne Paris Cite, Hop Bichat, AP HP,Dept Hosp Univ FIRE,FACT,INSERM,U 1148, Paris, France.;ICMS Royal Brompton Hosp, NHLI Imperial Coll, London, England. (author)
  • ten Berg, Jurrien M.St Antonius Hosp, Nieuwegein, Netherlands. (author)
  • Manassie, JennyBoehringer Ingelheim Ltd, Div Med, Bracknell, Berks, England. (author)
  • Kreuzer, JorgBoehringer Ingelheim Pharma GmbH & Co KG, Ingelheim, Germany.;Heidelberg Univ, Fac Med, Heidelberg, Germany. (author)
  • Blatchford, JonBoehringer Ingelheim Ltd, Div Med, Bracknell, Berks, England. (author)
  • Massaro, Joseph M.Boston Univ, Sch Publ Hlth, Boston, MA USA. (author)
  • Brueckmann, MartinaBoehringer Ingelheim Pharma GmbH & Co KG, Ingelheim, Germany.;Heidelberg Univ, Fac Med Mannheim, Mannheim, Germany. (author)
  • Ripoll, Ernesto FerreirosBoehringer Ingelheim Pharma GmbH & Co KG, Ingelheim, Germany. (author)
  • Oldgren, JonasUppsala universitet,Kardiologi,Uppsala kliniska forskningscentrum (UCR)(Swepub:uu)jonaoldg (author)
  • Hohnloser, Stefan H.Goethe Univ Frankfurt, Dept Cardiol, Frankfurt, Germany. (author)
  • Harvard Clin Res Inst, 930 Commonwealth Ave, Boston, MA 02215 USA.;Brigham & Womens Hosp, Div Cardiovasc, 75 Francis St, Boston, MA 02115 USA.;Harvard Med Sch, Boston, MA USA.Boehringer Ingelheim Pharma GmbH & Co KG, Ingelheim, Germany. (creator_code:org_t)

Related titles

  • In:Clinical Cardiology: Wiley39:10, s. 555-5640160-92891932-8737

Internet link

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view